Farnesyltransferase Inhibitors in Cancer Therapy

. Ed(s): Sebti, SM (Humana author USA); Hamilton, Andrew

ISBN 10: 0896036294 / ISBN 13: 9780896036291

Published by Humana Press Inc., 2000

About this Item

The recent explosion of knowledge gained from genes capable of causing cancer have opened up new avenues for designing anticancer drugs. This volume describes the efforts of several groups in the design and evaluation of these inhibitors. Editor(s): Sebti, SM (Humana author USA); Hamilton, Andrew. Series: Cancer Drug Discovery and Development. Num Pages: 280 pages, biography. BIC Classification: MJCL2; MMG. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 254 x 178 x 17. Weight in Grams: 732. . 2000. Hardback. . . . . Books ship from the US and Ireland.

Seller Inventory # V9780896036291

Bibliographic Details

• Title: Farnesyltransferase Inhibitors in Cancer Therapy
• Publisher: Humana Press Inc.
• Publication Date: 2000
• Language: English
• ISBN 10: 0896036294
• ISBN 13: 9780896036291
• Binding: Hardcover
• Condition: New

About this title

Synopsis

Cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farensyltransferase inhibitors (FTIs); geranylgeranyltransferase inhibitors (GGTIs) are also discussed as potential anticancer drugs. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors.

From the Back Cover

With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints.
Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors.